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INTRODUCTION 
There have been few epidemics as devastating and 
preventable as that caused by tobacco consumption. Cigarette 
smoking became highly prevalent through the 20th century; with a 
lag of several decades, the rise of smoking was followed by 
epidemic increases in the diseases now known to be caused by 
smoking, including lung and other cancers, heart disease, and 
chronic lung disease. By mid-century, epidemiologic studies were 
providing the initial evidence establishing that smoking caused 
these diseases. As the 21st century begins, smoking is on the rise 
in developing countries, even as it has started declining in the 
developed countries. 
Some of the first epidemiological studies on secondhand 
smoke and health were reported in the late 1960s [1-3]. One 
German physician, Fritz Lickint, used the term "passive smoking" 
in his 1939 book on smoking [4]. The 2006 Surgeon General's 
report uses the term "secondhand smoke," although the term 
"environmental tobacco smoke" (ETS) was used more frequently 
in earlier reports [5].  
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The first major studies on secondhand smoke and lung 
cancer in nonsmokers were reported in 1981[8,9], and by 1986 the 
evidence supported the conclusion that secondhand smoke was a 
cause of lung cancer in non-smokers, a conclusion reached by the 
International Agency for Research on Cancer (IARC)[7,10,11]. 
Subsequently, a now substantial body of evidence has continued to 
identify new diseases and other adverse effects of secondhand 
smoke, including increased risk for coronary heart disease [6,12-
15].  
The tobacco industry's campaign to discredit the evidence on 
active smoking initially and on secondhand smoke subsequently is 
now well documented as legal actions against the tobacco 
industry. There was an attempt to maintain seeming controversy 
among scientists even as the evidence mounted and supported 
converging conclusions by expert panels on the adverse effects of 
secondhand smoke. 
Environmental tobacco smoke (ETS) is a combination of 
side stream smoke and exhaled mainstream smoke, while passive 
smoking is defined as an involuntary exposure to ETS [16]. Little 
attention has been paid in the past to health consequences of ETS. 
There has been a growing concern that non-smokers exposed at 
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home or at work place may also face increased risks of diseases 
similar to those described in smokers [16]. 
Exposure to ETS reduces the blood’s ability to carry oxygen 
to the heart and compromises the ability of the myocardium to 
produce ATP using oxygen. These effects manifest as reduced 
exercise capacity in people exposed to ETS. Passive smoking over 
a period of ten years changes the intima /media ratio by enhancing 
the thickness of the vessel wall and by adversely affecting 
endothelial function. ETS adversely affects platelet function, 
depresses cellular respiration at the level of the mitochondria. It 
also potentates other risk factors like hypertension [17]. 
It is well known that cigarette smoking is associated with 
elevation of plasma lipids and changes in lipoprotein distribution 
[18]. Smokers have elevated serum uric acid levels and that these 
levels denote the level of oxidative stress imparted to the body by 
smoking [67]. Although the effect of passive smoking on human 
health has been established as a major risk factor, the effect of 
passive smoking on lipid profile and serum uric acid has not been 
well established. The present study is aimed at correlating the 
lipid profile and the serum uric acid in passive smokers and to 
prove their atherogenic potential. 
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                        AIM AND OBJECTIVES 
¾ To study the effects of passive smoking on lipid profile and 
to estimate serum uric acid among healthy women whose 
husbands are smokers. 
¾ To correlate the biochemical changes with the duration of 
exposure. 
¾ To assess the atherogenic potential of environmental tobacco 
smoke. 
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REVIEW OF LITERATURE 
The ancient Indians not only enjoyed its stimulatory effects 
of tobacco but also believed it has medicinal properties. Until the 
late 1880s, cigarette smoking was less frequent than other forms 
of tobacco usage, e.g., snuff. But the invention in 1880s of 
cigarette rolling machine followed by the development of safety 
matches tilted the balance in favor of cigarette smoking [19]. 
Tobacco smoke contains over 4000 different chemicals, 
many of which have adverse effects on human health and can 
contribute to the development of diseases such as heart disease, 
stroke and lung cancer. Cigarette smoking is addictive, because of 
the presence of the alkaloid nicotine and withdrawal of this causes 
the unpleasant side-effects of quitting. Cigarette smoking is also 
associated with a large number of physiological changes 
particularly in blood lipids and hemostatic factors that explain its 
role in coronary heart disease [20, 21]. 
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ENVIRONMENTAL TOBACCO SMOKE (ETS) 
(SECONDHAND SMOKE) 
The process of smoking produces three different types of 
tobacco smoke: 
(i) Mainstream smoke: the smoke directly inhaled through the 
burning cigarette by the smoker [22]. 
(ii) Exhaled mainstream smoke: The smoke breathed out by the 
smokers from their lungs. The composition of the 
mainstream and the exhaled mainstream smoke is likely to 
differ, some of the compounds in smoke being retained by 
the smoker or otherwise altered by the process [22]. 
(iii) Sidestream smoke: The smoke which drifts away from the 
burning end of the lit cigarette [22] . 
Mainstream and sidestream smoke consist of a large number 
of chemical carcinogens and other toxic substances, but undiluted 
sidestream smoke contains many compounds in far greater 
concentration. For example, side stream smoke contains greater 
amounts of ammonia, benzene, carbon monoxide, nicotine and the 
carcinogens 2-napthylamine, 4-aminobiphenyl, N-nitrosamine, 
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benzanthracene and benzopyrene per milligram of tobacco burned 
[23]. 
The particles of sidestream smoke are smaller than those of 
mainstream smoke, meaning that they may be inhaled deeply into 
the lungs and is considered by the Environment Protection Agency 
to be in the same class as radon and asbestos [23]. 
Although it has been considered that 85% of the smoke 
present in an average room in which smoking has occurred is 
composed of sidestream smoke, passive smokers still have a lower 
exposure to the harmful components of tobacco smoke than active 
smokers, who draw smoke directly into their lungs. Though the 
amount of smoke inhaled by smokers is only a fraction of the 
amount inhaled by smokers, a wealth of scientific evidence now 
exists showing that the breathing of tobacco smoke polluted by 
non-smokers can lead to serious harm [22]. 
Sidestream smoke has been found to contain virtually all the 
carcinogens identified in the smoke directly by smokers. Since 
side stream smoke does not pass through the filters of the 
cigarettes; it contains around 100 times the weight of the 
carcinogens of mainstream smoke. In an autopsy study of 
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nonsmoking women who had been married to smokers, 
significantly more epithelial, possibly precancerous lesions were 
found in the bronchi and pulmonary parenchyma than in wives of 
non-smokers. The risk of lung cancer was increased by 
approximately 20 percent for non-smoking women married to 
smokers. 
ESTABLISHED AND POTENTIAL HEALTH EFFECTS 
OF ENVIRONMENTAL TOBACCO SMOKE [24] 
Established 
¾ Increased lower respiratory infections in children 
¾ Increased respiratory symptoms in children 
¾ Reduced lung growth in children 
¾ Increased lung cancer in non-smokers 
¾ Irritation of the eyes, nose, throat and lower respiratory tract  
¾ Increased risk of cardiovascular disease 
Potential 
¾ Increased respiratory symptoms in adults 
¾ Reduced lung function in adults 
¾ Exacerbation of asthma 
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¾ Increased risk for non-respiratory cancers  
¾ Increased risk of sudden infant death 
¾ Reduced birth-weight 
¾ Increased risk of stroke 
Effects in children 
Exposure to ETS has been found to be a cause of slightly 
reduced birth weight, lower respiratory illnesses, chronic 
respiratory symptoms, middle ear disease, reduced lung function, 
asthma among children of school age and maternal smoking has 
been characterized as a major cause of sudden infant death 
syndrome (SIDS). 
Growth and development — Active smoking by pregnant 
women, resulting in secondhand smoke (SHS) exposure for the 
developing fetus, increases risk for a variety of adverse health 
effects in children including reduced birth weight as well, 
estimates of the reduction of birth weight associated with paternal 
smoking ranging from 24 to 31 grams [25,26]. Adverse effects of 
in utero or postnatal exposure to SHS on neuropsychological 
development and physical growth have also been postulated. Other 
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nonfatal effects possibly are growth retardation and congenital 
malformations [27-29].  
Sudden infant death syndrome — Sudden infant death 
syndrome (SIDS) refers to the unexpected death of a seemingly 
healthy infant while asleep. Studies measured maternal smoking 
after pregnancy, along with paternal smoking and household 
smoking generally. One report goes on to state that tobacco smoke 
exposure is one of the major preventable risk factors for SIDS [14, 
15].  
Lower respiratory tract illnesses — Infants with smoking 
parents have a significantly increased frequency of bronchitis and 
pneumonia during the first year of life [5, 30-33]. Presumably this 
association represents an increase in frequency or severity of 
illnesses that are infectious in etiology and not a direct response of 
the lung to the toxic components of SHS. An effect has not been 
readily identified after the first few years of life; this finding may 
be explained by higher exposures because of the time-activity 
patterns of young infants, which place them in close proximity to 
cigarettes smoked by their mothers.  
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Respiratory symptoms and illness —a greater frequency of 
the most common respiratory symptoms: cough, phlegm, and 
wheeze, in the children of smokers is seen. Having both parents 
smoke was associated with the highest levels of risk [7, 12, 15, 
34] 
Asthma —is a long-term consequence of the increased 
occurrence of lower respiratory infection in early childhood, or 
through other pathophysiological mechanisms including 
inflammation of the respiratory epithelium [5, 35, 36]. In utero 
exposures from maternal smoking may also affect lung 
development and increase the risk for asthma.. Maternal smoking 
during pregnancy also reduced ventilatory function measured 
shortly after birth. Exposure to secondhand smoke during 
childhood is also associated with increased prevalence of asthma 
in adults [37]. Guidelines for the management of asthma all urge 
reduction of SHS exposure at home [38].  
Lung growth and development — during childhood, 
measures of lung function increase are more or less parallel to 
increase in height. In a study of 193 high school athletes, for 
example, there was a fourfold increase in incidence of low forced 
expiratory flow 25 to 75 percent (FEF25-75) and/or cough in 
 18
athletes exposed to secondhand smoke compared with athletes not 
exposed [39].  
Middle ear disease —Exposure to SHS has been most 
consistently associated with recurrent otitis media and not with 
incident or single episodes. The evidence to date supports a causal 
relationship [5, 14].  
Dental caries — Exposure to SHS may be associated with 
an increased risk of dental caries in children. Studies found that 
elevated cotinine levels were associated with caries in deciduous 
but not permanent teeth [40].                                 
Effects in adults 
Lung cancer — the exposure to carcinogens with SHS is far 
less than the exposure that occurs with active smoking. On the 
other hand, exposure to SHS can begin in childhood and extend 
across the full lifespan. Genotoxic activity, the ability to damage 
DNA, has been demonstrated for many components of SHS [41-
43]. A number of studies have shown that SHS is associated with 
lung cancer. There appears to be a dose-response relationship 
between intensity of exposure and relative risk [5-10, 44, 45].  
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In a prospective cohort study of 91,540 nonsmoking women 
in Japan, standardized mortality ratios (SMRs) for lung cancer 
increased significantly with the amount smoked by the husbands 
[6]. The findings could not be explained by confounding factors 
and were unchanged when follow-up of the study group was 
extended [44]. In a population based, case-control study, 
household exposure to 25 or more smoker-years during childhood 
and adolescence doubled the risk of lung cancer, whereas exposure 
to fewer than 25 smoker-years did not increase the risk [46]. In 
another similarly designed study, tobacco use by the spouse was 
associated with a 30 percent increase in risk of lung cancer. The 
risk rose with increasing levels of pack-year exposure from the 
spouse; 80 or more pack-years of exposure was associated with an 
80 percent excess risk of lung cancer. A meta-analysis of 37 
published studies involving 4626 people with lung cancer found 
an excess risk of lung cancer of 24 percent (95% CI 13-36 
percent) if an individual lived with a smoker [48]. Based upon the 
available data, the United Kingdom's Scientific Committee on 
Tobacco and Health concluded that exposure to secondhand smoke 
is a cause of lung cancer [13]. The US Environmental Protection 
Agency has classified SHS as a Group A carcinogen, that is, a 
known human carcinogen [20].  
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The risk for the development of lung cancer in response to 
secondhand smoke may be influenced by genetics. One study 
found a significant increase in polymorphisms in the gene 
glutathione S-transferase M1 which is believed to play a role in 
detoxifying carcinogens in tobacco smoke; thus, mutations which 
decrease its activity could serve to promote tumorigenesis [50].  
Cardiovascular disease — the risk of CHD in active 
smokers increases with amount and duration of cigarette smoking 
and decreases quickly with cessation. Active cigarette smoking is 
considered to [51] increase the risk of cardiovascular disease by 
promoting atherosclerosis, increase the tendency to thrombosis, 
cause coronary artery spasm, increase the likelihood of cardiac 
arrhythmias, decrease the oxygen-carrying capacity of the blood, 
affect vascular endothelial cell function. 
It is biologically plausible that secondhand smoke could be 
associated with increased risk for CHD through the same 
mechanisms considered relevant for active smoking. One study 
found that 30 minutes of exposure to secondhand smoke in healthy 
young volunteers compromised coronary artery endothelial 
function in a manner that was indistinguishable from that of 
habitual smokers, suggesting that endothelial dysfunction may be 
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an important mechanism by which secondhand smoke increases 
CHD risk [52]. One study associated increased inflammatory 
markers including higher white blood cell counts and levels of C-
reactive protein, homocysteine, fibrinogen, and oxidized LDL 
cholesterol [53] with risk of CAD. A prospective cohort study 
performed in 2004 measured serum cotinine levels in non-smokers 
exposed to SHS [54]. After 20 years of follow-up, among the 2105 
men who were nonsmokers, the risk of CHD was increased in 
those with higher serum cotinine concentrations.  
In 2005, the California Environmental Protection Agency 
(CalEPA), established that 22,700 to 69,000 deaths from CHD 
were attributable to SHS in 2000 [15]. The American Heart 
Association's Council on Cardiopulmonary and Critical Care 
concluded in 1992 that SHS both increases the risk of heart 
disease and is "a major preventable cause of cardiovascular 
disease and death" [55].  
Respiratory symptoms and illnesses —Consistent evidence 
of an effect of passive smoking on chronic respiratory symptoms 
in adults has not been found. 
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Lung function — Exposure to secondhand smoke has been 
associated in cross-sectional investigations with reduction of 
several lung function measures. However, the findings have not 
been consistent [13]. 
Diabetes —a 15-year cohort study also found an increased 
incidence of glucose intolerance in young adults aged 18 to 30 
exposed to SHS [56].  
All-cause mortality —Nonsmoking adults who lived with 
smokers had about a 15 percent increase in adjusted mortality 
compared with those living in a smoke-free household [103] 
MEASUREMENT OF EXPOSURE TO 
ENVIRONMENTAL TOBACCO SMOKE 
Exposure to ETS, like most other environmental exposures 
is difficult to measure. Several methods could be used for 
assessment of exposure in population based research on exposure. 
They are: 
(i)  Direct environmental measurements: 
Nicotine is a widely used marker of ETS. Tobacco products 
are the principle source of nicotine and beyond trace 
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concentrations, vapor-based nicotine is specific to tobacco and 
therefore suitable for measurement of ETS. Numerous field 
studies have been carried out on the levels of nicotine in various 
indoor environments and environment nicotine levels have been 
found to correlate with number of cigarettes smoked. In 
environments where smoking is permitted, components of tobacco 
smoke can readily be measured in the air, including small particles 
in the size range that penetrates into the lung, carbon monoxide, 
nicotine, and benzene. The exposures of nonsmokers will also 
depend upon proximity to smokers, particularly during the time 
that they are actively smoking. Concentrations of particles in 
homes with smokers are typically at least double those of homes 
without smokers. Nicotine, present as a gas in SHS, can be readily 
measured in indoor air using either active or passive samplers. Its 
presence is highly specific for tobacco smoke, as there are no 
other sources. Benzene, which causes leukemia, is generated by 
tobacco combustion and may contribute to the increased risk of 
leukemia in active smokers compared with nonsmokers.  
(ii)  Personal monitoring: 
This may provide a better approximation of individual 
exposure than ambient monitoring. For epidemiological research, 
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personal monitoring of exposure to ETS has seldom been used, but 
it would be valuable in future research, particularly for the 
measurements of accumulated exposures. 
(iii) Questionnaires: 
Most population research into health effects of passive 
smoking has used questionnaires to collect information on the 
smoking habits of the spouse, other family members and 
companions in the workplace. Riboli et al (1990) showed that, 
when appropriately questioned, non-smoking women can provide 
descriptions of exposures to ETS that are consistent with urinary 
cotinine levels. Brownson et al (1993), Emerson et al (1995) also 
showed high degree of reliability in responses about of passive 
smoking. 
(iv) Biological markers: 
Secondhand smoke can also be documented by the 
measurement of biomarkers, that is, tobacco smoke components or 
metabolites of these components in body fluids of nonsmokers, 
including blood, urine, saliva, and also in hair. Studies using 
biomarkers show clearly that SHS-exposed nonsmokers absorb, 
metabolize, and excrete tobacco smoke components, including 
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nicotine and tobacco-specific carcinogens [13]. In nonsmokers, 
tobacco-smoke carcinogens have also been shown to be bound to 
cellular DNA and albumin as adducts, and nonsmokers 
experimentally exposed to SHS excrete NNAL, a carcinogenic 
nitrosamine found in tobacco smoke.            
PREVALENCE OF TOBACCO USE [58] 
The total no of tobacco users in the world has been 
estimated at 1.2 billion, which is expected to rise to 1.6 billion 
during 2020s. 
Tobacco is used for smoking as well as in smokeless form in 
India. Smoking of tobacco is mainly in the form of beedi, followed 
by cigarette, hookah, chillum, chutta, etc., some common forms of 
smokeless tobacco include khaini, manipuri tobacco, mava, 
mishri,etc., 
Careful review of Indian studies concluded that beedi 
smoking is also associated with diseases caused by cigarette 
smoking and results in similar physiological changes. Despite 
their small size their tar and carbon monoxide deliveries are 
similar to those of manufactured cigarettes. 
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Tobacco use in India 
According to national family health survey-2(1998 to 
99),30% of population 15 years and above 47% men and 14.5% 
women-either smoked or chewed tobacco, which translates to 
almost 195 million people,154 million men and 41 million women 
in India. 
Deaths due to tobacco use in India 
Findings from 3 cohort studies (National Sample Survey 
Organization) suggested that at least 63,000 persons died in 1986 
due to tobacco use. When the median risks as observed from these 
studies and prevalence of tobacco use, as found in the first nation-
wide study, were applied to the 1996 population it showed that 
about 800,000 persons in India might have died due to the tobacco 
habit in India. 
Magnitude of tobacco related diseases in India 
Magnitude of three major tobacco related disease entities 
was estimated based on a careful review of Indian literature on 
risk estimates, 
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For development of these diseases in India and prevalence of 
tobacco use in India 
Disease entity 
Total no in India  
1996 
Cases due to 
tobacco use 
Tobacco related cancer 
(incident cases) 
209810 154,320 
Coronary artery disease 
(prevalent cases) 
15,700,000 4,200,000 
Chronic obstructive lung 
diseases (prevalent cases) 
14,000,000 3,700,000 
 
 
PATHOPHYSIOLOGY OF SMOKING AND 
PATHOGENESIS OF ATHEROSCLEROSIS 
The major forms of disease associated with smoking, i.e., 
coronary artery disease, stroke, peripheral artery disease are 
sequel of atherosclerosis. Atherosclerosis begins in childhood with 
accumulation of lipid in monocytes and smooth muscle cells of the 
arterial intima to form fatty streaks. Aortic fatty streaks, which 
appear shortly after birth, are present in almost all children shortly 
after 10 years of age and increase rapidly with age. Fatty streaks 
in the coronary arteries appear by about 15 and 20 years of age. 
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Fibrous plaques are elevated lesions with a core of lipid and 
necrotic debris with a cap of smooth muscle and connective tissue. 
These appear only rarely before 20 years of age but increase 
rapidly in prevalence and extent between20 and 30 years of age. 
The fatty streaks progress to fibrous plaques at some 
anatomic sites by continued lipid deposition and proliferation of 
smooth muscle and connective tissue. However, those in other 
areas may remain innocuous fatty streaks or regress. 
When fibrous plaques increase in size and undergo 
vascularisation, hemorrhage or ulceration and thrombosis, they 
lead directly to arterial occlusion and infarction of the affected 
organ, or in abdominal aorta, to weakening of the arterial media 
and formation of an aneurysm. Only at this stage does clinical 
disease become manifest. 
Dyslipidemia- a risk factor for atherosclerotic disease 
The importance of lipoproteins in the pathogenesis of 
atherosclerotic disease is well-known. The use of ultracentrifuge 
which allows separation of plasma lipoproteins provided important 
data on the relationship between LDL cholesterol, possible VLDL 
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cholesterol and coronary artery diseases. The role of HDL 
cholesterol as protective fraction also emerged. 
LIPID EFFECTS OF SMOKING 
Acute lipid effects of smoking [59] 
Intravenous nicotine or nicotine inhaled from cigarette 
smoking raises plasma concentrations of Free Fatty Acids (FFAs) 
through enhanced lipolysis. FFA is mobilized from adipose tissue 
as a result of sympatho-adrenal stimulation. Increase in the 
delivery of FFAs to the heart results in increase in myocardial 
oxygen consumption through a metabolic stimulation independent 
of changes in mechanical activity of the heart. The higher 
incidence of myocardial infarction and ventricular arrhythmias in 
chronic smokers may be related to the elevated myocardial FFA 
concentration [20]. 
Chronic Lipid Effects 
The atherogenic process is influenced by the levels of 
different plasma lipoproteins. Long term exposure to tobacco 
smoke enhances oxidation of LDL and decreases plasma HDL 
levels. The greater risk of atherosclerosis to people who are 
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exposed to tobacco smoking may result from the HDL lowering 
effects of tobacco smoke [59].   
The free radicals entering the body are first trapped by 
serum aqueous and lipophilic antioxidants, which interact and 
provide greater protection against lipid peroxidation than any 
other antioxidant on its own. The total peroxyl radical trapping 
power of serum is calculated using sulfhydryl groups, vitamin E, 
uric acid and ascorbic acid. The end-products of lipid peroxidation 
in serum increases after passive smoking, which modify apo B in 
LDL, which leads to more rapid and unregulated uptake of LDL 
cholesterol by macrophages and as a result, formation of foam 
cells [67]. This modified LDL may also stimulate the release of 
free radicals, further modifying these lipoproteins. 
The HDL class can be divided into subclasses HDL-2 and 
HDL-3. Current evidence indicates that the anti-atherogenic effect 
of HDL is related to the HDL-2 subclass. Smoking reduces both 
subclasses. 
Smoking and hemostatic functions 
Some of the detrimental effects of tobacco smoke on 
hemostatic function are increased leukocyte, platelet aggregation 
 31
and adhesiveness. Smokers have been found to have higher levels 
of plasma fibrinogen and there is a direct relationship between 
plasma fibrinogen levels and incidence of heart disease and stroke 
in population. Studies have also found that the levels of a 
metabolite of thromboxane A2 are elevated in smokers.  In these 
people, the cardiovascular system is extremely sensitive to the 
effects of SHS than an active smoker.  
NATIONAL CHOLESTEROL EDUCATION 
PROGRAM (NCEP) [61] 
Adult treatment panel III 
The adult treatment plan of the National Cholesterol 
Education Program (NCEP) released its recommendations 
concerning the diagnosis and management of hyperlipidemia in 
adults. 
The risk factors recognized by ATPIII are as follows: 
Major risk factors (Exclusive of LDL cholesterol that modify 
LDL goals) 
¾ Cigarette smoking 
¾ Hypertension 
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¾ Low HDL cholesterol 
¾ Diabetes mellitus 
¾ Family history of premature coronary artery disease 
¾ Age (men 45 years; women 55 years) 
¾ Lifestyle risk factors 
¾ Obesity (BMI 30 kg/m2) 
¾ Physical inactivity 
¾ Atherogenic diet 
Emerging risk factors 
¾ Lipoprotein (a) 
¾ Homocysteine 
¾ Prothrombotic factors 
¾ Pro-inflammatory factors 
¾ Impaired fasting glucose 
¾ Sub clinical atherogenesis 
Note: HDL cholesterol 60mg/dl counts as a negative risk factor; 
its presence removes one risk factor from the total count.                                     
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Reference values 
The recommendations in patients more than 20 years 
Total cholesterol 
Desirable                      :  < 200 mg/dl 
Borderline high            : 200-239 mg/dl 
High-risk                      : ≥240 mg/dl 
LDL cholesterol-primary target of therapy 
Optimal                            : <100 mg/dl 
Near/above optimal         : 100-129mg/dl 
Borderline high               : 130-159mg/dl 
High                                : 160-189mg/dl 
Very high                         : ≥ 190 mg/dl 
HDL cholesterol 
Low                                   : <40mg/dl 
High                                   : ≥ 60mg/dl 
Triglycerides 
Desirable                            : <150 mg/dl 
Borderline                           : 150-199 mg/dl 
High risk                              : 200-499 mg/dl 
Very High                            : ≥500mg/dl 
           Screening is recommended in all adults more than 20 years 
and should include a fasting lipid profile repeated every 5 years. 
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MANAGEMENT OF HYPERLIPIDEMIA [61] 
The quantitative estimate of risk places individuals in one of 
the following treatment strata: 
Risk category 
LDL 
goal(mg/dl)
LDL level at 
which to 
initiate 
TLC(mg/dl) 
LDL level at 
which to consider 
drug therapy 
CHD or CHD 
risk 
equivalents 
(10 year risk 
>20%) 
<100 100 130mg/dl 
2+ risk factors 
(10 year risk 
20%) 
<130 130 10 year risk 10-
20%:130mg/dl  
10 year risk 
<10%:160mg/dl 
0-1 risk factor <160 160 190mg/dl 
 
Note: CHD equivalents 
Symptomatic carotid artery disease            Abdominal aortic aneurysm 
Diabetes mellitus                                         Peripheral arterial disease 
TLC (Therapeutic Lifestyle Changes) diet 
Saturated fat, 7% of calories, cholesterol-200 mg/day 
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Consider increasing viscous (soluble) fiber 10-25g/day), plant 
stanol/sterols (2g/day) as therapeutic options to enhance LDL 
lowering. 
Weight management 
Increased physical activity 
Drug therapy 
¾ Consider drug therapy simultaneously with TLC for CHD 
and CHD equivalents. 
¾ Consider adding drug to TLC after three months for other 
risk categories. 
Drugs affecting lipoprotein metabolism: 
HMG CoA reductase inhibitors 
e.g., Simvastatin, Pravastatin, Atorvastatin 
Bile acid sequestrant resins 
e.g., cholestyramine, cholestipol 
Nicotinic acid and its derivatives 
Fibrates 
e.g., benzafibrate, fenofibrate 
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BENEFITS OF SMOKING CESSATION 
Cessation of smoking consumption constitutes the single 
most important intervention in atherosclerotic disorders. Smoking 
cassation alone reduces the risk of a first heart attack by nearly 65 
percent. Trials of nicotine replacement therapy using either 
transdermal nicotine or nicotine chewing gum have both proven to 
greatly increase abstention rates after cessation. Nicotine 
replacement during early abstinence helps to relieve symptoms of 
withdrawal and increase quit rates. Although the nicotine used as a 
medication may be addictive, it appears to be very minimal. 
Although the elevated  cardiovascular risk associated with 
smoking decreases significantly after smoking cessation, the risk 
of cancer of the lungs, pancreas and stomach persist for more than 
a decade as do the risks of developing chronic obstructive 
pulmonary disease. Thus primary prevention remains the most 
important population based component of any smoking reduction 
strategy [24]. 
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MAJOR EFFORTS FOR TOBACCO CONTROL IN 
INDIA  
Recognizing the health effects of tobacco, the Government 
of India promulgated The Cigarette (Regulation of Production, 
Supply and Distribution) Act 1975. Under the act, all packages 
and advertisements are to carry a statutory warning “Cigarette 
smoking is injurious to Health” [58]. 
  The parliament committee on sub-ordinate legislation in its 
22nd report December 1995) made wide ranging observations, 
including strong and rotatory warning in regional languages on 
tobacco products, prohibition of smoking in public places like 
hospitals, dispensaries, educational institutions, conference rooms, 
domestic air flights, trains, buses, initiation of measures for 
awareness on tobacco through health infrastructure, educational 
institutions and mass media and initiation of efforts for persuasion 
of farmers to switch over to alternate crops. These cabinet 
guidelines were reiterated in 1998. 
Multi-sectoral approach for tobacco control 
The problem of tobacco in India is complex in view of 
sectors like health, agriculture, finance, mass-media, labor, 
 38
education, industry, welfare, etc., unorganized nature of work for 
many tobacco products, dependence of a large number of people 
on tobacco production and processing and need for action by many 
agencies. 
In July 1991, a national conference on tobacco and health 
was held. It recognized tobacco as a major public heath hazard and 
noted that consumption of tobacco is not compatible with the goal 
of ‘Health for All’. It also recognized that an integrated 
educational, legislative and agro economic strategy with an 
operational framework. Political, administrative, financial and 
report support structure is needed. The conference recommended 
establishment of a National Tobacco Control commission to plan, 
co-ordinate and monitor tobacco control activities. 
The Indian Council of Medical research (ICMR) conducted 
operational research product for involving schools and community 
volunteers in anti-tobacco education. The ICMR’s collaborative 
project with All India Radio also showed the mechanism of inter-
sectoral collaboration is cost-effective education through radio. 
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Community education on tobacco 
The eradication of tobacco habits would require concerted 
action resulting in a social change. Anti-tobacco education needs 
to be targeted at decision-makers, professionals and the general 
public, especially the youth. No Tobacco Day (31st May) has been 
a regular feature since 1988, which generally comprises of 
educational advertisements in newspapers along with programs 
and workshops on tobacco. Tobacco has been included as a topic 
in books brought out by the NCERT. 
Coverage of entire country for anti-tobacco education is a 
formidable job and cannot be achieved without active support 
from non-governmental organizations and mass media. They 
however, need support from the health departments for availability 
of reliable and impartial information on the subject. Support 
would be needed also from other related sectors like education, 
economics, agriculture, welfare, etc, 
CONTROL OF ENVIRONMENTAL TOBACCO                         
SMOKE EXPOSURE 
Exposure to SHS takes place in many different 
microenvironments. The contributions of different 
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microenvironments also depend upon age, sex, and other socio-
demographic factors. For children, the home is a dominant locus 
of exposure, while for adults the workplace and social 
environments may be significant loci. Distinct control strategies 
are directed at different environments. Public places, workplaces, 
and transportation environments are subject to regulation while 
the home is not. Education is needed to reduce passive smoking in 
the home environment.  
In general, the concentration of SHS in a particular indoor 
environment depends upon the intensity of smoking (the strength 
of the source), the rate of exchange of air in the space with 
outdoor air or other "clean" air, and the presence and effectiveness 
of any air cleaning devices. For public and commercial buildings, 
ventilation requirements are set by code. Air cleaning is also not 
sufficient if smoking is allowed [63].  
Public places and transportation environments — Since 
the mid-1980s, there has been increasing regulation at the local 
and state level to restrict or eliminate smoking in public places. 
Model policies and regulations have been developed and made 
available by a number of organizations, including the American 
Lung Association. Exposure can be completely eliminated by 
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banning smoking indoors. Simply segregating smokers and 
nonsmokers within the same airspace may reduce the exposure of 
nonsmokers to SHS but does not eliminate it [7].  
Workplaces —Model workplace smoking policies may 
involve either an outright ban or restriction of smoking to 
designated areas; some companies ban smoking altogether on their 
properties. In implementing a workplace smoking policy, smokers 
should be provided with opportunities to participate in smoking 
cessation programs and informed communication is needed for all 
employees. The efficacy of workplace smoking policies has been 
documented in studies involving measurement of airborne nicotine 
and also of the biomarker cotinine. One study demonstrated that 
policies that ban smoking in the workplace are the most effective 
and generally lower all nicotine concentrations.  
The home environment — the air quality of homes is not 
subject to direct regulation, and effective educational strategies 
are needed to reduce exposures in homes through such steps as 
encouraging smokers to go outside the home or to restrict smoking 
to a particular room or away from children. Neither air cleaning 
nor increasing ventilation is a sufficient control measure. 
Typically in homes, indoor air exchanges with outdoor air through 
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natural diffusion and the air exchange rate cannot be substantially 
increased, even by opening windows and doors to the extent 
possible.  
Air cleaners — A variety of devices are available for air 
cleaning, ranging from complex and expensive systems that are 
incorporated into the HVAC systems of buildings to simple 
tabletop devices and "smokeless ashtrays," that are purported to 
control SHS exposure at its source. In general, health care 
providers should advise against purchase of an air cleaning device 
as a strategy for controlling SHS exposure. 
THE ROLE OF THE HEALTH CARE PROVIDER 
Most smokers are aware of tobacco health risks and have a 
general knowledge of the risks of secondhand smoke exposure. 
However, they may not know about specific risks that might affect 
their decision to expose children or other family members to ETS. 
Smokers may not know that secondhand smoke exposure can 
cause lung cancer and cardiovascular disease in their spouses or 
contribute to asthma and otitis media in their children.  
Smokers may be more amenable to change at key points in 
their lives or the lives of their children- pregnancy, birth of a 
child, early childhood (e.g., child begins to imitate smoking 
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behavior or asks about smoking), acute illness of the child that is 
related to smoking (e.g., otitis media), exacerbations of asthma. 
Healthcare providers should use these events as "teachable 
moments". Providing parents who smoke with guidance in 
cessation or referral to cessation programs is considered part of 
family-centered care. Families should be encouraged to actively 
control tobacco exposure as a way to role model a smoke-free 
attitude for the child.  
Approaches for smoking cessation counseling are based 
upon the National Institutes of Health (NIH) and U.S. Public 
Health Service six-component clinical practice guidelines: 
Anticipate  -   provide age-appropriate education to parents and  
   children  
Ask    -   ask about ETS exposure and parental tobacco use at  
   every visit  
Assess  -    assess if the smoker is ready to quit  
Advise  -    advise parents and youth who smoke to quit  
Assist  -   provide information and referrals for those who are  
   ready to quit  
Arrange  
follow-up -  provide encouragement and help with  relapse  
   prevention. 
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In addition to encouraging abstinence, the physician should be 
familiar with counseling and therapeutic programs, strategies and 
intervention that promote cessation. Physicians should also participate in 
the public debate not only individually but also through medical 
societies and organizations. 
RESPONDING TO SPECIFIC CLINICAL QUESTIONS 
AROUND SECONDHAND SMOKE 
A number of situations that may arise in clinical practice 
and suggested approaches are given below. There are now 
extensive resources available on the health effects of passive 
smoking that can be used by physicians working in the public 
health domain.  
Pregnancy —The majority of women stop smoking while 
pregnant, but a substantial percentage of smoking women (about 
30 percent) continue to smoke; they need to be advised as to the 
adverse effects of their smoking for the fetus (including effects on 
growth and development) and for the continued adverse effects of 
their smoking after birth. The parents need to know that the 
father's smoking may be harmful to the unborn child as well.  
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Children at risk for asthma — Exposure to tobacco 
smoke should be avoided for the child at risk for asthma on the 
basis of a family history of asthma and allergies. During the first 
weeks after birth, infants whose mothers smoke have increased 
airway responsiveness, perhaps a precursor of asthma, and SHS 
exposure, particularly from maternal smoking, is a risk factor for 
asthma [13].  
Children with asthma — SHS exposure, particularly 
from parental smoking, is associated with increased symptoms, 
medication usage, and utilization of health services for asthma 
[64]. Guidelines for the management of asthma call for the 
elimination of SHS exposure in the home for children with 
asthma.  
Lung cancer and heart disease risk for adults — 
the causal conclusion with regard to lung cancer meant that 
nonsmokers should divorce smoking spouses. While divorce is a 
potential strategy to control exposure to SHS in the home, there 
are alternatives.  
Workplace exposures — health care providers can 
reasonably postulate that the exposure may be harmful. If asked 
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about workplace risks from these exposures, health care providers 
can reasonably reply that the exposure would increase risk to some 
extent and that it could be reduced or eliminated with a workplace 
smoking policy.  
Sick-building syndrome — Sick-building syndrome can 
be a complex clinical problem, requiring a clinical diagnosis in an 
individual to be based in a population context. Passive smoking 
should be considered as one of the factors that can contribute to 
the occurrence of sick-building syndrome. 
PREPARING TO QUIT 
Once you decide to quit smoking, the first step should be to 
set a quit date. Gradual reduction in smoking is occasionally 
successful as a means of quitting, but generally quitting "cold 
turkey" is more successful. Some people choose to switch to a 
brand of cigarettes that is lower in tar and nicotine as a prelude to 
quitting, but frequently this causes one to inhale more often or 
more deeply, counteracting the effect one tries to achieve.  
BEHAVIORAL METHODS OF QUITTING    
Behavioral approaches to smoking cessation can be done on 
your own or in individual or group sessions.  
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Problem solving/skills training — as mentioned, when 
preparing to quit smoking one needs to identify situations or 
activities that may increase his risk of smoking or relapse. Once 
one has identified his "danger situations," he needs to explore 
coping skills. Strategies to enhance coping may include making 
lifestyle changes to reduce stress and improve quality of life, such 
as starting an exercise program and learning relaxation techniques.  
Social support — Social support can be very helpful in 
quitting smoking and staying off cigarettes. Social support 
systems may include family and friends, our health care provider, 
a counselor, a telephone hotline, and support groups. 
Group counseling — Group programs are offered by a 
number of commercial and voluntary health organizations. They 
typically include lectures, group interactions, exercises on self-
recognition of your habit, some form of a tapering method leading 
to a "quit day," development of coping skills, and suggestions for 
relapse prevention.  
Hypnosis and acupuncture — Hypnosis and 
acupuncture are commercially popular stop-smoking methods.  
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PHARMACOLOGIC METHODS OF QUITTING  
Nicotine replacement therapy and bupropion are the most 
commonly used medications for smoking cessation.  
Nicotine replacement therapy — in the absence of 
nicotine, a smoker not only loses the good feelings nicotine 
induces but may also develop withdrawal symptoms. These 
include: depressed mood, insomnia, irritability, frustration or 
anger, anxiety, difficulty concentrating, restlessness, nicotine 
craving, decreased heart rate. 
Nicotine replacement therapy is designed to reduce the 
intensity of these symptoms while a smoker deals with the 
behavioral aspects of smoking cessation. It will not prevent the 
symptoms completely. Nicotine replacement therapy appears to be 
acceptably safe, even in people with known cardiovascular 
disease. Many smokers are able to quit without using nicotine 
replacement therapy, although it is available to virtually anyone.  
NICOTINE PREPARATIONS 
Individual smokers may find one form particularly effective. 
Combinations of these therapies may be helpful in some people 
[2].  
 49
Nicotine polacrilex (gum) — Nicotine gum contains 
nicotine bound to a polacrilex resin that allows release of the 
nicotine with chewing. For most people who smoke one pack per 
day or more, use of 2 mg nicotine gum on an as-needed basis 
produces blood levels of nicotine less than 40 percent of those 
associated with usual smoking. As a result, the intensity of 
discomfort is often reduced. In addition, since peak blood levels of 
nicotine are much lower with gum than with a cigarette, both the 
feelings of well being and the addiction potential of nicotine gum 
are less than those of cigarettes. Nevertheless, many smokers have 
become chronic gum users. Treatment is generally recommended 
for three to six months.  
There are disadvantages of using nicotine gum. Some people 
have a low oral pH that reduces the absorption of nicotine. 
Nicotine polacrilix lozenges are also available. They slowly 
release nicotine into the saliva in the mouth. The nicotine works 
similarly to the gum, as it must be absorbed in the mouth and not 
swallowed. Because the lozenges do not require chewing, they 
may be easier for some people to use.  
Transdermal nicotine systems (patch) — 
Transdermal nicotine delivers nicotine to the blood through a 
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patch placed on the skin. The highest formulation (21 to 22 
mg/patch) delivers nicotine at a rate that sustains a blood level 
about half as high as that found in a thirty cigarettes per day 
smoker. The combination of intensive behavioral programs and 
nicotine patches has produced very favorable smoking cessation 
rates. The patch may be more effective than the gum when an 
intensive behavioral program is not used. Treatment with nicotine 
patches is generally recommended at "full dose" for four to six 
weeks. The slow rise in blood nicotine levels with patches is 
believed to be associated with a low risk of addiction.  
Nicotine nasal spray — compared to the patch and gum, 
the nasal spray produces a relatively rapid rise in nicotine 
concentration in the blood that more closely mimics changes seen 
with smoking. While studies have clearly demonstrated the safety 
and effectiveness of the nicotine nasal spray, it has a greater 
chance of prolonging nicotine dependence than the other therapies.  
Nicotine inhaler — the nicotine inhaler has proved to be 
a safe and effective smoking cessation method. Because most of 
the nicotine is deposited in the mouth and delivered to the body 
through the mucous membrane in the mouth, nicotine absorption is 
relatively slow.  
 51
Bupropion — Bupropion is an antidepressant that has also 
been used to help a patient stop smoking. Bupropion may be more 
effective than nicotine replacement therapy, and combining the 
two may be even more effective. It is generally well tolerated, but 
it may cause dry mouth and insomnia. 
RELAPSE 
Smoking is now regarded as a relapsing disorder. Each quit 
should be regarded a victory, and the longer it lasts, the better. 
Relapse, however, may occur. Most relapses occur in the first 
week after quitting, when withdrawal symptoms are strongest. One 
should mobilize all his support resources (e.g., family, friends) 
during this critical time.  
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MATERIALS AND METHODS 
The present study was conducted at the Institute of Internal 
Medicine, Govt. General Hospital, Chennai, between August 2007 
and August 2007. One hundred married women in the age group of 
20 to 45 years who had never smoked were selected among the 
patient attendants and volunteers attending the Master Health 
Clinic for routine health checkups. 50 subjects were non-smokers 
with self-reported exposure to ETS at home from the husband 
(case) and 50 subjects were non-smokers with a non-smoking 
partner (controls). 
A standardized questionnaire was designed to collect 
information regarding demographic characteristics (age, 
residential are and occupation), history of hypertension, 
hyperlipidemia, diabetes mellitus, history of any drug intake and 
tobacco-chewing habits. Smoking and smoking habits of their 
husbands and other family members were noted in detail. Any 
exposure at workplace to ET was also noted. Subjects who use any 
form of tobacco were excluded from the study. 
Physical examinations including anthropometric (wt/ht2) 
measurements were performed. Blood pressure was measured in 
 53
all subjects. Routine investigations like fasting blood sugar, serum 
creatinine, urea was done in all cases. Electrocardiogram was done 
in all cases. 
Study group 
Cases and controls were defined 
(A) Cases (passive smokers) 
     Inclusion Criteria 
Healthy married, non-smoking women with smoking 
husband with self-reported exposure to passive smoke at home for 
at least 1hr/day for consecutive 3 years or more with or without 
exposure to ETS at workplace. 
Cases were also sub-grouped into two groups according to 
the duration of exposure 
1.  Exposed to ETS for 3 to 10 years. 
2.  Exposed to ETS for ≥ 11 years.  
Exclusion Criteria 
1. Tobacco chewing habits 
2. Subjects on any regular medications 
3. Oral contraceptive pill intake 
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4. Family history of premature deaths 
5. Pregnancy and lactation 
6. Body-mass index ≥30 
7. Diabetes mellitus, hypertension, IHD, hypothyroidism, 
nephritic syndrome, chronic liver diseases 
8. Alcohol intake 
9. Post-menopausal women  
10. Malignancies, steroid therapy 
(B) Control (Non-smokers) 
Healthy married women who were not exposed to passive smoke 
at home or at workplace. The dietary habits were almost the same 
among cases and controls. Same set of exclusion criteria was 
applied for controls also. 
Study design 
Since only females were included, it was a gender matched 
case-control study. 
Blood collection, storage & stability 
Venous blood samples were taken after 12 hours of 
overnight fasting from ante-cubital vein of horizontally resting 
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cholesterol esterase  
cholesterol oxidase 
peroxidase 
arm with 21 gauge needle; samples were transported to the lab 
within 1 hour. Serum is preferred. Heparinised or EDTA plasma 
can also be used. Serum or plasma samples should be used as soon 
as possible on the same day. 
Blood analysis 
Fasting blood sugar serum urea and serum creatinine were 
estimated. Fasting serum concentration of total cholesterol was 
estimated by enzymatic method, HDL cholesterol by 
phosphotungstate method and triglycerides by enzymatic 
calorimetric method by using commercial kits (from Bayer 
Diagnostics India Ltd) and the Express Plus auto-analyzer. Uric 
acid estimation was done by the uricase method. 
Estimation of cholesterol (Enzymatic method) 
Principle 
Cholesterol ester +H2O              Cholesterol+H2O2 
Cholesterol+O2       Chlesterol+H2O2 
2H2O2 +phenol+ 4-Aminoantipyrene    Red quinine +4H2O2 
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One ml of reconstituted reagent containing 
enzymes/chromogen and buffer (pipes buffer, Phenol, Sodium 
cholate) and 10 microlitre of the sample serum were mixed in a 
test tube, incubated at 37°Celsius for 5 minutes and read at 500 
nm. The concentration of cholesterol in the sample is directly 
proportional to the intensity of the red complex (red quinine) 
Estimation of HDL cholesterol (Phosphotungstate 
method) [26] 
Principle 
Chyomicrons, VLDL and LDL fractions in serum or plasma 
are separate from HDL by precipitating with phosphotungstic acid 
and magnesium chloride. After centrifugation the cholesterol in 
the HDL fraction, which remains in the supernatant is assayed by 
enzymatic method using the cholesterol esterase, cholesterol 
oxidase, peroxidase and the chromogen 4-aminoantipyrene and 
buffer 
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lipoprotein lipase 
glycerol kinase 
GPO 
peroxidase 
Estimation of triglycerides (Enzymatic Method) 
Principle 
 
Triglycerides+H2O     Glycerol+ Fatty Acid 
Glycerol + ATP         Glycerol-3-phosphate+ ADP 
Glycerol-3-phosphate+O2       Dehydroxyacetone phosphate+H2O2 
2H2O2 +4-aminoantipyrene+ADPS     Red quinone+4H2O 
         GPO     glycerol-3-phosphate oxidease 
         ADPS    N-ethyl-n-Sulfopropyl-n-anisidine 
The intensity of purple colored complex formed during the 
reaction is directly proportional to the triglycerides concentration 
in the sample and is measured at 546nm. 
LDL cholesterol was calculated according to the Friedwald 
equation. 
LDL=TC─ (HDL + Triglycerides/5) 
VLDL is calculated by the formula 
VLDL=TC─ (HDL+LDL) 
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uricase  
POD 
Uric Acid (Enzymatic method)  
This reagent kit is used for in vitro quantitative 
determination of uric acid in serum, plasma or urine. 
Principle:  
Uric acid is converted by uricase into allantoin  and 
hydrogen peroxide in the presence of peroxidase (POD) oxidizes 
the chromogen into a red colored compound which is read at 
500nm(492-550). The final color of the reaction is stable for 
fifteen minutes. 
Uric acid + 2H2O + O2             Allantoin +CO2 + H2O 
H2O2 + 4- Aminoantipyrine + DHBS             Red quinone  + H2O  +HCl 
          DHBS 3, 5- Dichloro-2-Hydroxybenzene Sulfonic Acid 
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OBSERVATION AND RESULTS 
The lipid profile obtained from 100 subjects, among whom 
50 were passive smokers (cases) and 50 non-smokers (controls) 
was analyzed. 
Distribution of cases and controls in relation to age-group 
Table 1: Distribution of cases and controls in relation to age 
Age(years) 
Cases(passive smokers)
No(%) n=50 
Controls(Non-smokers) 
NO.(%) n=50 
20-25 4(8) 6(12) 
26-30 23(46) 20(40) 
31-35 15(30) 15(30) 
36-40 8(16) 5(10) 
41-45 0(0) 4(8) 
Total Cholesterol 
The mean Total Cholesterol value in subjects not exposed to 
ETS (controls) was 166.08 ± 26.45 mg/dl, whereas the total 
cholesterol in women exposed to ETS was 181.64 ± 30.42 mg/dl 
(p=0.0104,statistically significant). 
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Table 2: Total cholesterol in non-smokers and passive smokers 
 Numbers(n) Mean total cholesterol (mg/dl) SD 
Non-
smokers(control) 
50 166.08 26.45
Passive 
smokers(cases) 
50 181.64 30.42
P=0.0104 
LDL Cholesterol levels 
The mean LDL Cholesterol in non-smokers was 96.44 
±28.42 mg/dl whereas the LDL cholesterol in passive smokers was 
113.27±34.54 (p=0.0089, statistically significant). 
Table 3: LDL cholesterol in non-smokers and passive smokers 
 Numbers(n) Mean LDL cholesterol (mg/dl) SD 
Non-
smokers(control) 
50 96.44 28.42
Passive 
smokers(cases) 
50 113.27 34.54
p=0.0089, statistically significant 
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HDL cholesterol levels   The mean HDL cholesterol in non-
smokers was 46 ± 9.3 whereas in passive smokers the mean HDL-
C was 43.98 ± 7.32(p=0.2248, statistically not significant). 
Table 4: HDL cholesterol in non-smokers and passive smokers 
 Numbers(n) Mean HDL cholesterol (mg/dl) SD
Non-
smokers(control) 
50 46 9.3
Passive 
smokers(cases) 
50 43.98 7.2
(p=0.2248, statistically not significant). 
Triglycerides 
The mean triglycerides in non-smoking women was 119.74± 
29.56 whereas the mean triglycerides in passive smokers was 
126.1±28.54 (p=0.275, statistically not significant). 
Table 5: Triglycerides in non-smokers and passive smokers 
 Numbers(n) Mean TGL (mg/dl) SD 
Non-
smokers(control) 
50 119.76 29.56
Passive 
smokers(cases) 
50 126.1 28.54
(p=0.275, statistically not significant). 
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VLDL Cholesterol levels 
The mean level of VLDL in non-smoking women was 
24.28±5.96 mg/dl whereas VLDL in those exposed to ETS was 
25.96±5.7, (p=0.235, statistically not significant). 
Table 6: VLDL Cholesterol in non-smokers and passive smokers 
 Numbers(n) Mean VLDL(mg/dl) SD 
Non-
smokers(control) 
50 24.28 5.96
Passive 
smokers(cases) 
50 25.96 5.7 
p=0.235, statistically not significant 
Serum uric acid  
The mean level of serum uric acid in non-smoking women 
was 4.52mg/dl whereas uric acid in those exposed to ETS was 
5.75mg/dl, (p=0.002, statistically significant). 
Table 7: Serum uric acid in non-smokers and passive smokers 
 Numbers(n) Mean serum uric 
acid(mg/dl) 
SD 
Non-
smokers(control) 
50 4.52 1.47
Passive 
smokers(cases) 
50 5.75 1.6 
p=0.002, statistically significant 
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Table 8: The lipid profile in women exposed to ETS with 
relation to duration of exposure 
Lipids 
Exposed to 
ETS 3-10 
years n=27 
Exposed to 
ETS≥11 
years n=23 
P value 
Mean 
Cholesterol(mg/dl)±SD
176.96±36.52 187.17±23.43 0.2546 
Mean LDL mg/dl ±SD 108.19±39.10 119.25±27.7 0.2617 
Mean HDL mg/dl ±SD 45.70±7.24 41.96±6.79 0.064 
Mean triglycerides 
mg/dl ±SD 
120.11±29.7 133.13±25.78 0.107 
Mean VLDL mg/dl  24.70±5.94 26.43±5.1 0.09 
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DISCUSSION 
Both the cases (exposed to ETS) and controls (not exposed 
to ETS) were comparable in terms of age, weight, body mass 
index and dietary habits. All the subjects were pre-menopausal 
women and all were housewives without exposure to ETS at 
workplace. 
The mean serum Total Cholesterol value among the non-
smokers was 166.08 ± 26.45 while in the passive smokers it was 
181.64 ± 30.42. The value was significantly higher in passive 
smokers. MP HOLAY et al [69] (2004) have demonstrated that 
mean cholesterol level is higher in passive smokers (169 ± 27.6 
mg/dl) than in non-smokers (151.6 ± 13 mg/dl). In the study 
conducted by Feldman et al (1991) [66] in adolescents, it was 
found that the ratio of total cholesterol to HDL cholesterol was 
8.9% greater in passive smokers than in non-smokers. These 
results suggest that passive smoking like active smoking leads to 
alteration in lipid profile predictive of an increased risk of 
atherosclerosis. 
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The mean LDL cholesterol level was 96.44 ± 28.42mg/dl in 
non-smoking women while the LDL Cholesterol in passive 
smokers was 113.27± 34.54 mg/d [67]. This is in accordance with 
the study conducted by VALKONEN M et al who observed that 
mean LDL cholesterol in passive smokers was 110.33±27.6mg/dl 
and in non-smokers was 93.54±26.23 mg/dl. MP HOLAY et al 
(2004) [69] observed high mean LDL levels (106±20.4mg/dl) in 
passive smokers than in non-smokers (97.26±15.5mg/dl). 
Acute exposure of a non-smoking subject to passive 
smoking resulted in deterioration of serum oxidant defense, 
accelerated lipid peroxidation and accumulation of LDL 
cholesterol in human macrophages. These events were observed 
even after a very short period (30 minutes) of passive smoking. 
Indeed it has previously been suggested that the cardiovascular 
system is extremely sensitive to the chemicals in environmental 
tobacco smoke. Further the oxidative stress induced by second 
hand smoke may have more prominent effects on a non-smoking 
subject than an active smoker whose cardiovascular system has 
adapted to cigarette smoke [67, 68]. 
The mean HDL cholesterol in non-smokers was higher 
(46±9.3 mg/dl) than in passive smoking women (43.98±7.2 
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mg/dl). This is accordance with studies by ELLIS J. NEUFELD et 
al (1997) [70] who found out that the mean HDL Cholesterol 
levels in children from households with cigarette smokers were 
lower (38.7±1.2mg/dl) than in controls (43.6±mg/dl). In the study 
conducted by MP HOLAY et al (2004) the HDL Cholesterol level 
was 51.48±6mg/dl in passive smokers and 55.24±6.7mg/dl in non-
smokers [69]. 
The mean triglycerides in non-smoking women were 
119.76±29.56 mg/dl whereas in passive smoking women it was 
126.1±28.46mg/dl.  This is similar to that observed by MP 
HOLAY et al (2004) [69] who found that mean triglycerides in 
passive smokers was 125.76±19.2 mg/dl and in non-smokers was 
116.6±14.20mg/dl. 
 Mean VLDL Cholesterol is also higher in passive smokers 
(25.96±5.7mg/dl) than non-smokers (23.58±5.96mg/dl). 
In the present study as shown, total cholesterol, LDL and 
VLDL increase with duration of exposure to ETS, though 
statistically not significant. There is considerable reduction in 
levels of HDL with increasing duration of exposure to ETS. 
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The mean serum uric acid in non-smokers was 4.52±1.47 
mg/dl whereas in those exposed to ETS it was 5.75±mg/dl. Miia 
Valkonen and Timo Kuusi had shown similar results in their 
studies [67]. 
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STUDY LIMITATIONS 
1. The study is a hospital-based study and may not be 
representative of the general population. 
2. There may be alternative pathways that may be responsible 
for cardiovascular complications in passive smoking. 
3. This study does not  elucidate the causal relationships 
between the risk factors and outcome. 
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SUMMARY 
1. The mean serum Total Cholesterol value among the non-
smokers was 166.08 ± 26.45 while in the passive smokers it 
was 181.64 ± 30.42. The value was significantly higher in 
passive smokers. 
2. The mean LDL cholesterol level was 96.44 ± 28.42mg/dl in 
non-smoking women while the LDL Cholesterol in passive 
smokers was 113.27± 34.54 mg/d. 
3. The mean HDL cholesterol in non-smokers was higher 
(46±9.3 mg/dl) than in passive smoking women (43.98±7.2 
mg/dl). 
4. The mean triglycerides in non-smoking women were 
119.76±29.56 mg/dl whereas in passive smoking women it 
was 126.1±28.46mg/dl. 
5. Mean VLDL Cholesterol is also higher in passive smokers 
(25.96±5.7mg/dl) than non-smokers (23.58±5.96mg/dl). 
6. The mean serum uric acid in non-smokers was 4.52±1.47 
mg/dl whereas in those exposed to ETS it was 5.75±mg/dl.  
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CONCLUSION 
Passive smoking like active smoking is unfavorably 
associated with lipoprotein metabolism and it predisposes the 
individual to premature atherosclerosis and its consequences like 
myocardial infarction, stroke, etc., Passive smoking also increases 
serum uric acid and this may serve as a crude marker to the 
amount of oxidative stress imparted to the body by the process of 
passive smoking.  
To conclude the present study provides further evidence that 
environmental tobacco smoke including smoke at workplace is 
likely to cause adverse health effects in non-smoking women. 
Despite the efforts to control smoking most women are still 
exposed to tobacco smoke at home and at work. They are also 
unaware of the hazards of passive smoking and are in a 
disadvantaged position to protect themselves from ETS. Urgent 
public health measures are required to reduce smoking in India so 
as not only to protect women and children from environmental 
tobacco smoke but also men from the hazards of active smoking. 
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SCOPE FOR FURTHER STUDIES 
The exact role of the changes in the various lipid 
components in the pathogenesis of atheromatous changes is still to 
be elucidated. The SHS-induced alterations in the lipid profile 
have just been thrown light upon by this study. The various 
mechanisms of uptake of the altered lipids by the macrophages 
and their conversion to atherogenic foam cells is an interesting 
and a potentially fruitful field to work up on. 
Ascorbic acid, sulfhydryl groups, uric acid, vitamin C and 
vitamin A have been postulated as the first line of defense against 
the added anti-oxidants added to any body system. Research work 
is possible on the various other less-studied and more specific 
components of the anti-oxidant system. 
Pharmacology oriented studies regarding the combination 
therapies for smoking cessation is a possible arena of interest. 
Physicians interested in preventive medicine shall take up a 
possible research on the environmental aspects of SHS control. 
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ANNEXURE 
PROFORMA 
CHANGES IN SERUM LIPID LEVELS, URIC ACID DUE TO 
PASSIVE SMOKING IN HEALTHY FEMALES 
1.   NAME                                                                                         
2.   AGE                                                                                                                   
3.   SEX                                                                                                                    
4.    OP NO                                                                                                             
5.    RESIDENTIAL                                                                                                 
6.    OCCUPATION                                                                                                 
7.    MENSTRUAL HISTORY                                                                                 
8.    HISTORY OF TREATMENT FOR HYPERTENSION                               
9.    HYPERLIPIDEMIA                                            
10.  DRUG INTAKE                                                                           
11.  TOBACCO CHEWING HABITS                                                                 
12.  SMOKING HABITS OF HUSBAND/OTHER FAMILY MEMBERS   
13.  SMOKE EXPOSURE AT WORKPLACE                                                     
14.  HISTORY OF ORAL CONTRACEPTIVE PILL INTAKE                              
15.  FAMILY HISTORY OF PREMATURE DEATHS                                         
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16.  PREGNANCY AND LACTATION                                                                    
17.  HISTORY OF TREATMENT FOR ISCHEMIC HEART DISEASE             
18.  HYPOTHYROIDISM                                                                                        
19.  NEPHROTIC SYNDROME                                  
20.  CHRONIC LIVER DISEASE                                                                         
21   ALCOHOL INTAKE                                                                 
EVALUATION   
1. HEIGHT                                
2. WEIGHT                                    
3. BODY MASS INDEX                        
4. BLOOD PRESSURE                      
5. FASTING BLOOD SUGAR                      
                        BLOOD UREA                                                 
           SERUM CREATININE 
6. FASTING LIPID PROFILE                                  
7. SERUM URIC ACID             
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ABBREVIATIONS 
1. ETS: Environmental tobacco smoke 
2. IARC: International Agency for Research on Cancer 
3. SHS: Secondhand smoke 
4. SIDS: Sudden infant death syndrome 
5. SMR: Standardized mortality ratio 
6. CAD: Coronary artery disease 
7. LDL: Low-density lipoprotein 
8. HDL: High-density lipoprotein 
9. VLDL: Very low density lipoprotein 
10.  TC: Total cholesterol 
11.  TGL: Triglycerides 
12.  CalEPA: California Environment Protection Agency 
13.  NCEP: National Cholesterol Education Program 
14.  ATP III: Adult treatment plan III 
15.  ICMR: Indian Council for Medical Research 
16. EDTA: Ethylene diamine tetra-acetic acid 
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Duration of 
exposure to 
ETS 
Blood biochemistry 
(mg/dl) 
Serum lipid 
(mg/dl) S.No Name Age Sex 
At 
home 
At 
work
Sugar
(F) Urea Creatinine
Total 
cholesterol LDL HDL TGL VLDL
Serum uric 
acid 
(mg/dl) 
1 Dhanalakshmi 25 F nil nil 92 22 0.8 171 110 41 94 20 2 
2 Durga 30 F nil nil 98 26 1 122 68 43 71 15 3 
3 Geetha 25 F nil nil 96 22 0.8 179 104 46 103 21 5.1 
4 Jayanthi 28 F nil nil 94 24 0.8 213 149 41 122 25 6.2 
5 Suseela 30 F` nil nil 97 22 0.8 199 132 38 104 21 6 
6 Parvathi 32 F nil nil 101 23 1 184 127 38 102 21 3 
7 Usha 33 F nil nil 96 22 1 148 82 41 133 21 5.2 
8 Pushpa 26 F nil nil 98 24 0.8 147 83 45 102 21 5.5 
9 Priya 42 F nil nil 90 20 0.8 167 102 45 106 22 7 
10 Santhi 28 F nil nil 109 26 1.2 156 96 39 111 23 4.2 
11 Kamala 25 F nil nil 116 24 0.8 166 94 46 135 28 5 
12 Maragatham 29 F nil nil 110 26 0.8 116 63 36 88 19 4 
13 Muniyammal 28 F nil nil 100 20 0.8 111 44 41 134 28 7 
14 Sakunthala 29 F` nil nil 90 20 1.2 146 92 31 120 25 4 
15 Samruthbegum 33 F nil nil 90 23 1.1 161 87 55 103 21 6.1 
16 Vasantha 35 F nil nil 108 22 0.8 172 118 33 111 23 7 
17 Rani 38 F nil nil 97 22 0.8 177 114 41 115 24 4.5 
18 Kamatchi 35 F nil nil 72 20 0.8 194 140 31 123 25 1.9 
19 Kala 29 F nil nil 76 16 0.8 201 140 39 119 24 2.8 
20 Rukmani 38 F nil nil 78 20 0.8 158 98 43 91 19 4 
21 Arogyamary 27 F nil nil 90 22 0.8 151 88 31 168 34 6.6 
22 Gunasundari 42 F nil nil 100 20 1.1 147 98 31 96 20 3.9 
23 Krishnaveni 35 F` nil nil 117 30 0.8 161 105 45 63 13 4.6 
MASTER CHART
CONTROL 
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24 Bhuvaneswari 32 F nil nil 78 22 0.8 157 95 45 93 19 2.9 
25 Sanmugapriya 42 F nil nil 90 20 1 172 107 41 125 26 3.7 
26 Radha  33 F nil nil 80 20 0.8 243 154 45 102 21 5.1 
27 Dhanaselvi 26 F nil nil 90 26 0.8 131 49 59 121 33 5.9 
28 Gunaselvi 31 F nil nil 100 26 0.9 171 78 63 154 25 6 
29 Prabhavathi 29 F nil nil 98 24 0.8 165 85 66 127 32 3 
30 Sampornam 24 F` nil nil 96 22 0.8 165 85 56 127 32 5.2 
31 Malathi 27 F nil nil 105 24 0.8 191 115 39 189 24 5.5 
32 Sudha 26 F nil nil 100 23 0.8 176 90 55 161 39 3.1 
33 Gandhamani 31 F nil nil 96 20 0.8 137 56 63 95 20 4.2 
34 Valli 28 F nil nil 88 24 0.8 141 57 61 119 25 5 
35 Ramani 25 F nil nil 86 22 0.9 216 139 41 190 39 4 
36 Ponnammal 25 F nil nil 90 22 1 181 95 56 157 32 3.9 
37 Manjula 29 F nil nil 104 22 1 201 128 35 196 40 4 
38 Chinnammal 33 F nil nil 90 20 0.8 165 87 57 111 23 6.1 
39 Sangeetha 26 F` nil nil 84 24 0.7 131 45 52 177 36 7 
40 Isaimathi 42 F nil nil 80 22 0.9 103 37 49 92 19 4.5 
41 Hemavathi 28 F nil nil 90 22 0.8 151 77 51 122 25 1.9 
42 Biwi Jahn 23 F nil nil 90 20 0.8 148 76 56 87 18 2.8 
43 Pushpalatha 27 F nil nil 98 26 0.7 147 74 39 145 30 4 
44 Parvathi 38 F nil nil 106 26 0.9 204 137 51 93 19 5.8 
45 Anitha 34 F nil nil 96 28 0.7 197 131 46 106 22 3.9 
46 Kanagavalli 25 F nil nil 90 20 0.9 205 115 66 125 26 4.6 
47 Aswini 26 F nil nil 100 22 1 176 108 45 121 25 2.9 
48 Palaniammal 31 F` nil nil 96 20 1.1 166 35 55 138 28 7.7 
49 Thilagavathi 28 F nil nil 86 20 1.2 153 87 45 109 23 2.1 
50 Ramanammal 40 F nil nil 83 35 1.0 169 65 45 101 21 3 
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Duration of 
exposure to 
ETS 
Blood biochemistry 
(mg/dl) 
Serum lipid 
(mg/dl) S.No Name Age Sex
At 
home
At 
work
Sugar
(F) Urea Creatinine
Total 
cholesterol LDL HDL TGL VLDL
Serum 
uric 
acid 
(mg/dl)
1 Chinnamani 29 F 10 nil 90 20 0.8 130 48 58 120 24 3.7 
2 Chitra 35 F 15 nil 98 26 0.9 171 78 63 154 32 8.1 
3 Mangalam 30 F 6 nil 106 36 0.8 223 150 35 196 40 5 
4 Dhanakodi 28 F 5 nil 96 28 0.8 165 87 57 111 23 4 
5 Anandhi 29 F` 6 nil 98 24 1 191 105 52 177 36 5.7 
6 Kumari 27 F 5 nil 105 22 0.8 103 37 49 92 19 6.8 
7 Santhakumari 26 F 5 nil 100 20 0.8 151 77 51 122 25 4 
8 Jayammal 29 F 8 nil 100 20 0.8 151 77 51 122 25 5.9 
9 Mahalakshmi 30 F 9 nil 88 22 1 121 42 59 105 22 8 
10 Babyammal 32 F 11 nil 86 22 1 155 93 37 129 27 9.1 
11 Padma 28 F 9 nil 90 22 0.8 276 210 43 123 25 3.7 
12 Pattu 32 F 12 nil 104 24 0.8 186 127 41 94 20 8.1 
13 Bhagyam 40 F 18 nil 80 22 1.2 191 118 47 137 28 3 
14 Adhilakshmi 35 F` 14 nil 84 24 0.8 184 123 43 95 20 3.6 
15 Seetha 23 F 3 nil 80 22 0.8 222 162 44 88 18 7.5 
16 Rajeswari 30 F 10 nil 90 22 0.8 184 123 43 95 20 3.1 
17 Maliga 27 F 7 nil 90 20 0.8 160 98 41 112 23 6.2 
18 Nagammal 23 F 4 nil 98 26 0.9 157 88 47 65 14 3.9 
19 Mangammal 40 F 20 nil 106 26 1 225 150 47 147 30 3 
20 Saroja 35 F 14 nil 96 28 1 166 108 36 117 24 6.4 
21 Ammu 30 F 9 nil 90 20 0.8 191 128 42 129 23 7 
22 Saradha 36 F 15 nil 100 22 0.7 223 152 50 111 23 4.5 
CASES 
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23 Pachaiyamal 33 F` 11 nil 96 20 0.9 204 129 48 141 29 4.6 
24 Sowri 34 F 11 nil 87 20 0.8 177 116 40 113 23 7.3 
25 Pavunammal 27 F 5 nil 90 20 0.8 186 120 41 131 27 8.8 
26 Panchavarnam 28 F 15 nil 90 22 0.8 151 98 32 111 22 5 
27 Tamilselvi 35 F 12 nil 90 20 0.8 130 25 48 141 29 4.4 
28 Rebecca 28 F 5 nil 98 26 0.8 182 130 28 126 26 4.5 
29 Savithri 38 F 15 nil 106 26 0.9 203 135 37 161 33 7 
30 Govindammal 30 F` 9 nil 96 28 1 226 150 50 134 28 6 
31 Deepa 33 F 13 nil 90 20 1 185 150 50 134 28 5.9 
32 Bommi 37 F 17 nil 100 22 0.8 215 149 38 145 30 7.2 
33 Periyathai 40 F 17 nil 96 20 0.7 171 105 42 127 26 6.8 
34 Anjalai 32 F 11 nil 86 20 0.9 172 116 36 94 20 7.7 
35 KhurshedBegum 40 F 18 nil 96 22 1 181 126 34 10 23 4.7 
36 Indra 27 F 7 nil 90 20 0.8 187 116 46 133 27 8.1 
37 Kalavathi 28 F 9 nil 98 26 0.8 157 83 41 169 35 4.1 
38 SaithoonBeevi 30 F 9 nil 96 22 0.9 161 103 41 91 19 9 
39 Sengammal 30 F` 9 nil 95 24 0.8 219 165 43 109 23 10 
40 Yasodha 35 F 16 nil 96 22 0.8 193 121 37 179 37 5.7 
41 Alamelu 35 F 15 nil 98 24 0.8 198 128 37 173 35 4 
42 Rajasri 27 F 7 nil 90 20 0.7 138 63 53 117 24 6.2 
43 Manimegalai 26 F 5 nil 108 26 0.9 181 127 35 102 21 3.1 
44 Kamroonnisha 22 F 3 nil 96 24 0.8 168 105 41 117 24 4.1 
45 Nithya 39 F 18 nil 110 26 0.8 200 131 41 147 30 6.8 
46 Andal 33 F 10 nil 90 20 0.7 199 121 47 159 33 7.9 
47 Dharani 28 F 7 nil 90 20 0.9 180 111 47 114 24 4.9 
48 Panchavarnam 24 F` 3 nil 108 23 0.7 180 110 48 74 16 3 
49 Tamilselvi 35 F 15 nil 97 22 0.9 199 144 43 167 34 4.3 
50 Rebecca 35 F 14 nil 92 22 1 203 128 46 153 31 6.1 
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